Invasive breast carcinoma

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

This study compares two surgical approaches for breast cancer: one that removes extra tissue around the tumor (routine cavity shave margins) and one that uses a special device (Savi Scout®) to guide removal of only suspicious margins. About 204 women with early-stage breast cance…

This study tests a shorter, more focused radiation treatment (hypofractionated partial breast irradiation) for women with early-stage breast cancer. The goal is to see if targeting only the tumor site can reduce side effects and improve cosmetic outcomes compared to standard whol…

This study is for people with HER2-positive stage II to IIIa breast cancer whose tumors completely disappear after initial chemotherapy and targeted therapy before surgery. The goal is to see if using fewer chemotherapy drugs after surgery can still keep the cancer from coming ba…

This phase II trial studies whether giving radiation therapy before surgery can shrink hormone receptor-positive, HER2-negative breast tumors. About 25 participants will receive radiation followed by breast surgery. The goal is to see if this approach reduces the amount of normal…

This early-phase trial tests a combination of two drugs, cyclophosphamide and veliparib, in people with HER2-negative breast cancer that has spread or cannot be surgically removed. The main goal is to find the safest dose and check for side effects. Up to 35 participants will rec…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …

This phase III trial tests whether a structured weight loss program can lower the risk of breast cancer recurrence in overweight or obese women who have been treated for early-stage breast cancer. Researchers will compare women who join the program with those who do not, tracking…

This trial studies women with breast cancer who need a mastectomy, radiation, and immediate breast reconstruction using their own abdominal tissue (DIEP flap). The goal is to compare giving radiation before surgery versus after surgery. Researchers will measure patient satisfacti…

This phase III trial tests whether adding pembrolizumab (Keytruda) after standard chemotherapy can help prevent triple-negative breast cancer from coming back. Over 1,100 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or placebo. The stud…

This phase II trial tests whether adding an immunotherapy drug (atezolizumab) to a targeted therapy (olaparib) works better than olaparib alone for advanced non-HER2-positive breast cancer that has a BRCA mutation. About 81 patients with locally advanced or metastatic disease are…

This large phase 3 trial studied over 5,000 women with hormone receptor-positive, HER2-negative breast cancer that had spread to 1-3 lymph nodes. Participants received standard hormone therapy (tamoxifen or an aromatase inhibitor) either alone or with chemotherapy. The goal was t…

This study tests whether a newer drug, Z-Endoxifen, works better than the standard tamoxifen for postmenopausal women with advanced ER+/HER2- breast cancer. About 81 participants will receive one of the two hormone therapies to see which delays cancer growth longer. The goal is t…

This early-phase trial tested a drug called Z-endoxifen in 62 people with a type of breast cancer that has spread or come back. The goal was to find the safest dose and check for side effects. Z-endoxifen works by blocking estrogen, which some breast cancers need to grow.

This study tests giving a short course of focused radiation before breast cancer surgery, using MRI for precise planning. The goal is to treat a smaller area of the breast and possibly reduce side effects. About 39 women with early-stage breast cancer will receive five radiation …

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests whether adding the targeted drug pyrotinib to standard chemotherapy can better shrink tumors before surgery in people with a common type of early breast cancer (HR-positive, HER2-low). About 160 adults with high-risk, early-stage breast cancer will be randomly as…

This study is testing whether giving radiation therapy tailored to each patient's risk level can reduce arm swelling (lymphedema) while still controlling cancer in women with early-stage breast cancer that has spread to a sentinel lymph node. Participants receive either whole bre…

This phase 3 trial tests whether adding entinostat to the hormone therapy exemestane helps control advanced hormone receptor-positive breast cancer better than exemestane alone. About 600 patients with locally advanced or metastatic breast cancer are participating. The study meas…

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (carboplatin and paclitaxel) before surgery helps shrink tumors in people with stage II-III triple negative breast cancer. About 67 participants will receive either chemo alone or…

This phase 2 trial is testing whether adding the immunotherapy drug cemiplimab (Libtayo) to standard chemotherapy can eliminate more cancer before surgery in people with high-risk or locally advanced breast cancer. The study enrolls 36 participants with either hormone receptor-po…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that remains after initial chemotherapy and surgery. About 415 participants with stage II-III breast cance…

This study tests whether analyzing the genetic makeup of a patient's triple-negative breast cancer tumor can help doctors choose the most effective treatment. Patients with newly diagnosed, early-stage triple-negative breast cancer receive either standard chemotherapy or a person…

This study looks at whether a 16-20 week exercise and coaching program can reduce inflammation and protect blood vessel health in Black and White women undergoing chemotherapy for breast cancer. Researchers will measure fitness, blood vessel function, and quality of life. The goa…

This trial investigates whether breast cancer patients with cancer in 1-2 sentinel lymph nodes can safely avoid additional armpit surgery (axillary clearance). The study compares survival and cancer recurrence in patients who have the extra surgery versus those who do not. The go…

This study looks at how well older patients (65 and up) with advanced or metastatic breast cancer tolerate a chemotherapy drug called Abraxane. The goal is to see what side effects occur and whether the drug can control tumor growth. Participants receive Abraxane intravenously, a…

This study tests whether a daily pill (Z-endoxifen) plus a monthly shot (goserelin) can slow or stop estrogen-driven breast cancer growth in premenopausal women. About 87 participants will take the drugs for up to 24 weeks before surgery. The main goal is to see if the treatment …

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can help the immune system attack HER2-negative breast cancer more effectively. About 46 adults with locally advanced disease will receive a short course of these d…

This study looks at giving a single dose of radiation directly to the tumor site during breast-conserving surgery in women aged 60 and older with early-stage, hormone-sensitive breast cancer. The goal is to see if this shorter, targeted approach controls the cancer as well as sta…

This study tests whether losartan, a drug already used for high blood pressure, can reduce scarring (fibrosis) caused by radiation therapy in breast cancer patients. 43 women who had breast surgery and need radiation will receive either losartan or a placebo. Researchers will mea…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…

This study compares a 1-week radiation course to a standard 3-week course for women with node-positive breast cancer. The goal is to see if the shorter treatment is just as effective at preventing cancer from coming back while reducing the risk of lymphedema (arm swelling). About…

This study is testing whether women over 55 with a specific low-risk type of breast cancer (luminal A) can avoid radiation after lumpectomy. Instead, they take hormone-blocking pills for 5 years. Researchers are tracking 500 women for 10 years to see how many have the cancer come…

This study tests a shorter course of radiation (hypofractionated) to the breast and nearby lymph nodes in 137 women with node-positive breast cancer. The goal is to see if this approach reduces arm swelling (lymphedema) and other side effects while still preventing cancer from co…

This phase III trial tests whether adding tucatinib to standard T-DM1 therapy works better than T-DM1 alone at preventing breast cancer from coming back. It involves over 1,000 patients with HER2-positive breast cancer who still have cancer cells after initial treatment. The stud…

This study tests whether giving radiation over just 5 days in a row, instead of the usual longer schedule, is safe and works well for breast cancer patients who have had a mastectomy and breast reconstruction. The goal is to prevent cancer from coming back in the chest or nearby …

This study tests whether the drug ixabepilone can help people with HER2-negative breast cancer who still have significant cancer after standard chemotherapy. About 116 participants will either receive ixabepilone or standard care. The goal is to see if ixabepilone improves outcom…

This early-phase trial tests a combination of two drugs—veliparib and carboplatin—in people with HER2-negative breast cancer that has spread. The goal is to find the best dose and see if the combo is safe. Veliparib may help carboplatin work better by stopping cancer cells from r…

This study tests a newer targeted therapy, trastuzumab deruxtecan (T-DXd), against an older one, trastuzumab emtansine (T-DM1), in about 1,600 people with high-risk HER2-positive breast cancer who still have cancer after initial treatment. The goal is to see if T-DXd can better p…

This study tests a combination of targeted drugs (ribociclib, tucatinib, trastuzumab, with or without fulvestrant) for HER2-positive breast cancer. In the first part, it looks at safety in patients whose cancer has spread. In the second part, it compares these drugs to standard c…

This phase II trial tests a drug called sacituzumab govitecan in 44 patients with HER2-negative breast cancer that has spread to the brain. The drug is a targeted antibody that delivers chemotherapy directly to cancer cells. The goal is to see if it can shrink brain tumors or slo…

This phase II trial is testing a type of radiation called proton beam therapy for women with early-stage breast cancer (stage 0 to II). The goal is to see if this targeted approach can kill cancer cells while causing less damage to normal tissue, leading to fewer side effects and…

This study compares two approaches for women with early-stage invasive breast cancer undergoing breast-conserving surgery: no axillary surgery versus sentinel lymph node biopsy. The goal is to see if avoiding axillary surgery leads to the same cancer outcomes while reducing compl…

This study tests whether giving the immunotherapy drug pembrolizumab (Keytruda) along with a small dose of radiation to the tumor before standard treatment (surgery, chemotherapy, or radiation) is safe and helps the immune system fight breast cancer. About 66 people with operable…

This phase 2 trial tests whether combining immunotherapy (avelumab) with other drugs can shrink tumors in people with advanced triple-negative breast cancer that has spread or come back. About 145 participants will receive one of several drug combinations, including avelumab plus…

This study tests whether combining two treatments—thermal ablation (using heat to destroy tumor cells) and stereotactic radiosurgery (precise, high-dose radiation)—can better control cancer that has spread to the spine and is pressing on the spinal cord. About 60 adults with vari…

This study tests whether adding the drug panitumumab to standard chemotherapy helps shrink tumors more effectively in people with a rare and aggressive type of breast cancer called triple-negative inflammatory breast cancer. About 42 participants will receive chemotherapy before …

This Phase 2 trial is testing whether a combination of two targeted drugs (trastuzumab and pertuzumab) given as a single shot under the skin, along with standard hormone therapy, can prevent cancer from returning after surgery in people with early-stage, hormone receptor-positive…

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This study looks at a way to help women under 40 with breast cancer keep their ability to have children after chemotherapy. Before starting chemo, participants receive hormone injections and tamoxifen to stimulate their ovaries, then eggs or embryos are frozen. The goal is to see…

This study compares a 1-week radiation schedule to the standard 3.1-week schedule for people with early-stage breast cancer who have had lumpectomy. The goal is to see if the shorter course controls cancer just as well while causing fewer side effects. About 72 adults with ductal…

This phase II trial tests a single, high-dose radiation treatment given before surgery for early-stage breast cancer. The goal is to see if this approach leads to good or excellent cosmetic results and reduces the need for multiple radiation sessions. About 110 women with small, …

This study tests whether an inactivated Pseudomonas aeruginosa injection, combined with an iodine wash, can reduce complications like infection and capsular contracture in women undergoing immediate breast reconstruction with implants after cancer surgery. The trial involves 100 …

This study looks at women with early-stage breast cancer who need both radiation and chemotherapy after surgery. It compares giving these treatments at the same time versus one after the other, to see if the combined approach has similar side effects and outcomes. About 81 women …

This phase II trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard hormone therapy (letrozole or fulvestrant) and the targeted drug palbociclib can shrink tumors in postmenopausal women with newly diagnosed stage IV estrogen receptor-positive bre…

This phase III trial tests whether a shorter course of radiation (hypofractionated) after mastectomy can prevent cancer recurrence with fewer side effects than standard radiation. About 900 patients with stage II-IIIa breast cancer are participating. The study compares complicati…

This study tests whether adding the experimental drug onvansertib to standard chemotherapy (paclitaxel) can safely shrink tumors in people with triple-negative breast cancer that has spread. About 50 adults with advanced or metastatic disease will receive the combination. The goa…

This study compares two types of radiation therapy for women with early-stage breast cancer after lumpectomy. One group receives standard CT-guided radiation, while the other receives a newer MRI-guided approach. The goal is to see if MRI-guided radiation works just as well at pr…

This study tests whether giving an extra dose of radiation (a boost) before breast cancer surgery is safe and helpful. About 103 people with early-stage breast cancer that hasn't spread will receive the boost, then standard radiation and surgery. The goal is to see if this approa…

This study tests whether adding pembrolizumab (Keytruda) to sacituzumab govitecan helps people with a common type of advanced breast cancer (HR+/HER2-). About 110 participants receive either the combination or sacituzumab alone. The goal is to see if the combo delays cancer growt…

This phase IIb trial is testing whether combining a nightly fast (time-restricted eating) with the diabetes drug metformin can slow the growth of breast cancer cells before surgery. The study includes 120 women with early-stage breast cancer or a precancerous condition called DCI…

This phase 2 study tests the drug olaparib in 114 people with metastatic breast cancer whose tumors have mutations in certain DNA repair genes (like BRCA1, BRCA2, ATM, PALB2, and others). Olaparib is a PARP inhibitor that may kill cancer cells by blocking their ability to fix dam…

This study tests a high-dose, precise radiation therapy called SBRT for people with breast cancer who cannot undergo surgery. Fifteen participants will receive five radiation treatments and be followed for five years to check for side effects and tumor response. The goal is to se…

This study tests a shorter radiation treatment (partial breast irradiation) for women with early-stage breast cancer or a pre-cancer called DCIS. Instead of treating the whole breast for 5-7 weeks, radiation is given only to the area where the tumor was removed, for just 2 weeks.…

This phase 2 trial tests whether a special PET/CT scan using a radioactive tracer (FDG) can predict how well HER2-positive breast cancer responds to standard chemotherapy before surgery. About 235 patients with stage II-III HER2+ breast cancer will get the scan early in treatment…

This phase 2 trial tests whether a PET scan using a radioactive form of estrogen (FES) can predict how well endocrine therapy works in 99 women with newly diagnosed metastatic breast cancer. The scan lights up cancer cells that have estrogen receptors, helping doctors see if the …

This study is testing whether a simple breath test can tell if a woman has breast cancer. Researchers are collecting breath samples from 1000 women — half with breast cancer and half without — and analyzing them with a mass spectrometer. The goal is to see if the chemical signatu…

This pilot study tests a smart bra that measures skin temperature to find breast abnormalities, including cancer. About 70 women with or without breast cancer will wear the device to see how well it detects tumors. If it works, it could offer a simple, portable screening option.

This large study is testing whether a new laser-based blood test can help screen for breast cancer. Researchers will compare blood samples from women with and without breast cancer to see if the test can accurately spot the disease. If it works, it could offer a less invasive way…

This early-stage study tests an experimental vaccine designed to prevent cancer in adults with BRCA1 or BRCA2 gene mutations. The vaccine is given alone or with another drug, followed by a mild electric pulse to help it enter cells. Researchers want to see if it is safe and wheth…

This study tests whether adding a photo guide to standard counseling helps reduce anxiety and depression in women with early-stage breast cancer who are about to start radiation therapy. About 62 participants will either receive standard verbal counseling alone or with a pictoria…

This study tests whether a remotely delivered program that combines mindfulness, physical activity tracking, and social support is acceptable and feasible for people with metastatic breast cancer. The program lasts 8-12 weeks and includes a wearable activity tracker and weekly ch…

This study tests whether a shorter course of higher-dose radiation (hypofractionated) is as good as or better than standard radiation for early-stage breast cancer. About 300 women with ductal carcinoma in situ or early invasive breast cancer are participating. The main goal is t…

This study compares two creams, Aquaphor and Miaderm, to see which one better treats skin irritation caused by radiation therapy in breast cancer patients. About 208 women with early-stage breast cancer will use one of the creams during their radiation treatment. The goal is to f…

This study looks at whether women aged 65 and older with early-stage, estrogen-positive breast cancer can safely have a lumpectomy without also removing and testing nearby lymph nodes (sentinel node biopsy). The goal is to see if skipping this extra step leads to cancer coming ba…

This study is testing a very short course of radiation therapy for women with early-stage breast cancer. Instead of weeks of treatment, participants receive whole breast radiation with a targeted boost over just 5 days. Researchers will track how the breast looks and feels, and h…

This study compares a 3-week course of radiation to the standard 5-week course for breast cancer patients who need radiation to the lymph nodes. The goal is to see if the shorter schedule is just as effective at preventing cancer from coming back, while causing less arm swelling …

This study is testing whether listening to calming classical music twice a day can help women with breast cancer feel less anxious and depressed during surgery and chemotherapy. Researchers will also check if music affects certain substances in the blood linked to stress and nerv…

This study looks at whether using a Fitbit activity tracker along with health coaching can help reduce persistent pain and improve well-being in young Hispanic women who had breast cancer surgery. The trial will enroll 25 women who have had surgery at least six months ago and sti…

This study tests whether text message reminders and phone counseling help women with early-stage breast cancer take their daily hormone therapy pills as prescribed. About 1,167 women will be split into groups: some get usual care, others get texts and/or motivational interviewing…

This study looks at whether a genetic test on tumor samples can predict how well HER2-negative breast cancer will respond to standard treatments like chemotherapy or hormone therapy. About 1,100 people with stage I-III breast cancer are taking part. The goal is to see if this tes…

This pilot study is testing whether wearable activity trackers, like fitness watches, can help monitor fatigue in people with pancreatic or breast cancer who are undergoing treatment. Researchers want to see if patients will use the device daily and find it easy to use. The study…

This study looks at whether a special type of breast scan, called molecular breast imaging, can help doctors predict how well chemotherapy is working in women with invasive breast cancer. About 96 women will get the scan before, during, and after treatment. The goal is to see if …

This study looks at whether certain genes make African American women with breast cancer more likely to develop nerve damage (pain, numbness, tingling) from common chemotherapy drugs called taxanes. About 249 women with stage I-III breast cancer will receive either docetaxel or w…

This study looks at how normal breast tissue appears on MRI and mammogram to see if it can help predict breast cancer risk. Researchers are comparing images and health information from over 2,000 women, including those with and without breast cancer. The goal is to better underst…

This pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…

This study aims to create a large collection of blood and tissue samples from people with breast cancer, as well as those at high risk. The samples will be stored and used for future research to better understand, diagnose, and treat breast cancer. Participants will also be asked…

This registry follows 94 women aged 50 and older with early-stage, low-risk breast cancer who received a single dose of radiation directly to the tumor site during lumpectomy (IORT). The goal is to monitor cancer recurrence, side effects, and patient satisfaction over time. Becau…

This study tests a special PET scan (FES) that tracks estrogen receptors in breast cancer tumors. Researchers want to see if changes in scan results before, during, and after hormone therapy can show how well the treatment is working. The study involves adults with estrogen recep…

This study looks at how breast cancer treatment affects quality of life in women of different ages. Researchers are asking 650 women recently diagnosed with early-stage breast cancer to fill out questionnaires about their physical and emotional well-being. The goal is to understa…

The PRECISION trial is studying whether women with a specific type of early-stage breast cancer can safely avoid radiation therapy after having a lumpectomy. Participants have tumors that are small, hormone receptor-positive, HER2-negative, and low-grade. A gene test called Prosi…

This study follows 810 young women aged 18-45 with early-stage breast cancer to understand how treatment affects their menstrual cycles and quality of life. Participants complete questionnaires every six months for up to 42 months. The goal is to identify factors that lead to ear…

This study looks at how different breast cancer treatment decisions, like choosing between a lumpectomy or mastectomy, affect women's quality of life and emotional distress. Researchers followed 345 women with early-stage breast cancer and their partners to measure cancer-related…

This study looks at genetic changes in blood and tumor samples from women with advanced hormone receptor-positive, HER2-negative breast cancer who are being treated with palbociclib and endocrine therapy. By comparing genetic material from the cancer tissue with that found in the…

This study collects blood and tissue samples from 300 people with breast cancer that has spread or come back. The goal is to create a large research registry that helps doctors understand why tumors spread and why people respond differently to treatments. Participants provide sam…

This study follows 202 postmenopausal women with early-stage, hormone-sensitive breast cancer who choose to skip radiation after lumpectomy and take only hormone therapy. Researchers track cancer recurrence over 10 years to see if this approach is safe for this low-risk group. Th…

This study is testing a new lab test called the RNA Disruption Assay (RDA) to see if it can tell how well breast cancer is responding to chemotherapy. Researchers will take small tissue samples (biopsies) from the tumor at specific times during treatment and analyze them. The goa…

This study looks back at nearly 3,000 women with early-stage invasive breast cancer to see if routine blood test results, along with tumor details, can help predict how the disease will progress. Researchers will track cancer recurrence and survival over time. The goal is to find…

This study looks at how the spread of breast cancer to lymph nodes under the arm relates to long-term outcomes. Researchers are following 2,467 patients to see if certain patterns of lymph node involvement are linked to cancer returning or survival. The goal is to better understa…

This study looks at whether the small white moons at the base of fingernails (lunula) can predict how well breast cancer patients respond to chemotherapy before surgery. Researchers will track 188 patients to see if lunula status is linked to tumor disappearance and side effects.…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study looks at why women in the Hauts-de-France region of France may wait longer to start breast cancer treatment, even though they get cancer at similar rates as elsewhere. Researchers will track 500 women from their first symptom to their first treatment, breaking down del…

This study planned to give high doses of vitamin D to women with breast cancer before their surgery. Researchers wanted to see if the vitamin would change certain markers in the cancer cells. However, the study was withdrawn before any participants were enrolled, so no results ar…

This study follows over 1,100 women with early-stage, hormone-sensitive breast cancer who took the EndoPredict® gene test. Researchers want to see if those classified as 'low risk' can safely receive only hormone therapy without chemotherapy. The goal is to confirm that 10-year s…

This early-stage study tests a new type of marker that can be seen more clearly on ultrasound. It is placed in lymph nodes where breast cancer has spread. The goal is to see if the marker is safe, stays in place, and helps surgeons find the cancer during surgery. About 15 people …

This study looks at how breast cancer and its treatments impact the quality of life for patients in Martinique. Researchers will survey 133 adults with invasive breast cancer to understand their physical and emotional well-being, as well as how long treatment takes. The goal is t…

This study looks at how chemotherapy given before surgery affects the immune system in people with operable breast cancer. Researchers will collect blood samples to see if certain immune cells can predict how well the tumor responds to treatment. The goal is to better understand …

This study takes tumor tissue from 50 women with invasive breast cancer and grows mini 3D versions called organoids in the lab. These organoids are used to collect tiny particles called extracellular vesicles, which naturally seek out tumor cells. The goal is to use these particl…

This study looks at whether women with small breast cancers (under 5 cm) and no signs of cancer in their lymph nodes on ultrasound can safely skip sentinel lymph node biopsy during breast-conserving surgery. About 1,734 women are being randomly assigned to either have the biopsy …

This study follows 100 women with breast or gynecologic cancers to see if their diet before chemotherapy is linked to levels of a protein called hepcidin, and whether hepcidin levels affect how much chemo they can receive. The goal is to understand if eating certain foods might h…

This study collects blood, tissue, and saliva samples from 7,000 people—both those with breast cancer and healthy volunteers. Researchers at Memorial Sloan Kettering will use these samples to study what causes breast cancer and find better ways to prevent, detect, and treat it. N…

This study follows 253 breast cancer patients aged 70 and older over five years. Researchers collect data on treatments, side effects, and quality of life to understand what helps older adults stick with their care. The goal is to find ways to improve outcomes and tailor treatmen…

This study looks at how well a medicated gel (afimoxifene) is absorbed through the skin of the breast in women who have had radiation for breast cancer. Researchers want to understand if differences in skin type or past radiation change how much gel gets into the breast tissue. T…

This study planned to test whether MRI-guided focused ultrasound could destroy breast tumors before mastectomy. The procedure was to be done under local anesthesia and sedation. However, the trial was withdrawn before enrolling any participants, so no results are available.

This study follows 500 adults aged 18-65 who completed chemotherapy for certain cancers and are in remission. Researchers will check for 19 possible late side effects over 5 years, including heart, lung, and hormone problems. The goal is to catch these issues early and connect pa…